Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vertex Achieves Gene-Editing Milestone With First Ever CRISPR Therapy Approval

Nov 16 2023

• By Andrew McConaghie

Related Content

Gene Editing: Exa-Cel Panel Review Raises Practical Concerns About Theoretical Risks

Nov 07 2023

Vertex Gears Up For Major Milestones, Starting With Sickle Cell Launch And Pain Drug Readout

Nov 07 2023

Can Beam Keep Up With Sickle Cell Gene Therapy Frontrunners? Investors Are Unconvinced

Oct 20 2023

Related Companies

Vertex Pharmaceuticals Incorporated

CRISPR Therapeutics AG

Bluebird Bio

Additional Topics

Approvals Commercial Gene Therapy Innovation Rare Diseases Regulatory Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.